Skip to content
Screener

Exelixis EXEL Business Segments — Cost of goods sold

Similar metrics at other companies

Chewy logo
CHWYReportable Segment — Cost of goods sold
$2.35B+7.0%
MSC Industrial Direct Co. logo
MSMReportable Segment — Cost of goods sold
$616.68M+7.5%
SIFCO Industries logo
SIFReportable Segment — Cost of goods sold
$20.78M+19.1%
Powell Industries logo
POWLReportable Segment — Cost of goods sold
$208.68M+6.9%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — Cost of goods sold
$1.95M-58.3%
Eos Energy Enterprises, Inc. logo
EOSEReportable Segment — Cost of goods sold
$117.58M+155%

Other financials

Income statement

See full
Revenue$628.7M+10.6%
Gross profit$608.0M+10.8%
Operating income$248.4M+16.3%
Net income$212.1M+14.7%
EPS (diluted)$0.82+26.2%

Balance sheet

See full
Cash & equivalents$281.4M+71.2%
Total debt$165.9M-7.7%
Total equity$1.8B-9.3%
Total assets$2.5B-6.9%

Cash flow

See full
Operating cash flow$307.7M+528%
CapEx$6.8M+140%
Free cash flow$300.9M+552%

Valuation

See full
Market cap$14.25B+40.4%
Enterprise value$14.14B+39.0%
P/E16.6×-0.3×
P/S5.9×+1.3×

Profitability

See full
Gross margin96.5%-0.1pp
Operating margin39.9%+8.5pp
Net margin35.3%+8.3pp
FCF margin48.1%+14.3pp

Returns & leverage

See full
Return on equity44.4%+15.4pp
Debt / equity0.1×0.0×
Current ratio3.5×-0.1×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.

The source filing: Exelixis’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:13 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q3 2026
Accession
0000939767-26-000098
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Collaboration revenues55,66548,247111,50090,411
Total revenues628,690568,2611,239,5021,123,708
Operating expenses:
Cost of goods sold20,65719,47040,61038,642
Research and development211,987200,356411,903412,589
Selling, general and administrative147,632134,859287,234272,042
Total operating expenses380,276354,685739,747723,273
Income from operations248,414213,576499,755400,435

Item 1. Financial Statements.

FAQ

What is Exelixis's business segments — cost of goods sold?
Exelixis (EXEL) reported business segments — cost of goods sold of $20.66M in Q2 2026.
How has Exelixis's business segments — cost of goods sold changed year-over-year?
Exelixis's business segments — cost of goods sold increased by 6.1% year-over-year, from $19.47M to $20.66M.
What is the long-term trend for Exelixis's business segments — cost of goods sold?
Over 3 years (2022 to 2025), Exelixis's business segments — cost of goods sold has grown at a 13.1% compound annual growth rate (CAGR), from $57.91M to $83.7M.
What does business segments — cost of goods sold mean?
Includes the direct costs attributable to the production and manufacturing of the company's pharmaceutical products. This encompasses raw materials, manufacturing overhead, and logistics required to bring the drugs to market.

Ask your AI about Exelixis's business segments — cost of goods sold.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude